Los Angeles, CA – Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer, is pleased to announce the awarding of a new patent for a vertical take-off and landing (VTOL) cargo delivery drone with variable center of gravity.
The design is ideal for Beyond Visual Line of Sight (BVLOS) and for transporting goods in hard to reach areas or flight over people at night.
US Patent No. 10,807,707 is an unmanned aircraft system (UAS) configured for both vertical take-off and landing (VTOL) and fixed-wing flight operations includes forward, and aft wing assemblies mounted to the fuselage, each wing assembly including port and starboard nacelles terminating in motor-driven rotors powered by an onboard control system capable of adjusting rotor speeds.
The UAS may transition between a powered-lift VTOL configuration to a winged-flight configuration by shifting its center of gravity forward, pivoting the wing assemblies from a powered-lift position perpendicular to the fuselage to a winged-flight position parallel to the fuselage.
The forward rotor blades may be folded back so that the aft rotors may provide primary thrust for winged flight operations. Onboard attitude sensors may detect rotor or control failures, to which the control system responds by triggering a conversion to the winged-flight configuration for recovery operations.
Draganfly views this patent as an important addition to its robust patent portfolio and believes it to be a core innovation for the industry and the drone delivery vertical.
Draganfly recently announced it had been selected by Coldchain Technology Services, LLC to immediately develop and provide flight services of a robust vaccine delivery payload for use in critical regions for drone delivery of the COVID-19 vaccine.
Coldchain Technology Services, LLC provides comprehensive solutions for healthcare supply chain management for multiple government and commercial clients, including the US Army, the Centers for Disease Control and Prevention, Reserve Component forces, Johnson & Johnson brands, Chicago Department of Public Health, and others and has been leading the deployment of COVID-19 vaccines throughout the United States.
Polaris Market Research estimates the medical drone market at USD 947.6 million by 2027. Facts and Factors estimates the global drone package delivery market was estimated at USD 530 million in 2019 and expected to grow at a compound annual growth rate of 42% from 2020 to 2027.
“With the signing of a signature customer and now this key industry patent we are confident in our role as an important global player in drone delivery space.” said Cameron Chell, CEO of Draganfly. “This showcases Draganfly’s continued focus on IP and highlights the strength and innovation of our engineering team.”
Draganfly Inc. (CSE: DFLY; OTCQB: DFLYF; FSE: 3U8) is the creator of quality, cutting-edge software and systems that revolutionize the way organizations can do business and service their stakeholders. Recognized as being at the forefront of technology for over 22 years, Draganfly is an award-winning, industry-leading manufacturer and technology developer serving the public safety, agriculture, industrial inspections, security, and mapping and surveying markets. Draganfly is a company driven by passion, ingenuity, and the need to provide efficient solutions and first-class services to its customers around the world with the goal of saving time, money, and lives.
For more information on Draganfly, please visit us at www.draganfly.com.
For additional investor information, visit https://www.thecse.com/en/listings/technology/draganfly-inc, https://www.otcmarkets.com/stock/DFLYF/overview or https://www.boerse-frankfurt.de/aktie/draganfly-inc.
This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements include, but are not limited to, statements with respect to the successful utilization and integration of the Company’s technology. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here in, including but not limited to: the potential impact of epidemics, pandemics or other public health crises, including the current outbreak of the novel coronavirus known as COVID-19 on the Company’s business, operations and financial condition, the successful integration of technology, the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties disclosed under the heading “Risk Factors“ in the Company’s most recent filings filed with securities regulators in Canada on the SEDAR website at www.sedar.com. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements’ best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.